SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

5 marketing jobs

Deciphera Pharmaceuticals logo
3 weeks ago

Associate Director, Marketing – Romvimza

Deciphera Pharmaceuticals

Waltham, MA (On-site)Full time$174K/yr – $239K/yr
Deciphera Pharmaceuticals logo
3 weeks ago

Senior Manager, Marketing Operations

Deciphera Pharmaceuticals

Waltham, MA (On-site)Full time$130K/yr – $179K/yr
Deciphera Pharmaceuticals logo
3 weeks ago

Senior Manager, Marketing Operations

Deciphera Pharmaceuticals

Waltham, MA (Hybrid)Full time$130K/yr – $179K/yr
Deciphera Pharmaceuticals logo
6 weeks ago

Associate Director, Brand Marketing (Hematology)

Deciphera Pharmaceuticals

Waltham, MA (Hybrid)Full time$174K/yr – $239K/yr
Deciphera Pharmaceuticals logo
2 months ago

Associate Director, Marketing – Romvimza

Deciphera Pharmaceuticals

Waltham, MA (On-site)Full time$174K/yr – $239K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

5 jobs
Deciphera Pharmaceuticals logo

Associate Director, Marketing – Romvimza

Deciphera Pharmaceuticals

Waltham, MA (On-site)

$174K/yr - $239K/yrIn-houseFull-timeSenior level10+ years exp.
3 weeks ago
Deciphera Pharmaceuticals logo

Senior Manager, Marketing Operations

Deciphera Pharmaceuticals

Waltham, MA (On-site)

$130K/yr - $179K/yrIn-houseFull-timeSenior level8+ years exp.
3 weeks ago
Deciphera Pharmaceuticals logo

Senior Manager, Marketing Operations

Deciphera Pharmaceuticals

Waltham, MA (Hybrid)

$130K/yr - $179K/yrIn-houseFull-timeSenior level8+ years exp.
3 weeks ago
Deciphera Pharmaceuticals logo

Associate Director, Brand Marketing (Hematology)

Deciphera Pharmaceuticals

Waltham, MA (Hybrid)

$174K/yr - $239K/yrIn-houseFull-timeSenior level10+ years exp.
6 weeks ago
Deciphera Pharmaceuticals logo

Associate Director, Marketing – Romvimza

Deciphera Pharmaceuticals

Waltham, MA (On-site)

$174K/yr - $239K/yrIn-houseFull-timeManager10+ years exp.
2 months ago
Deciphera Pharmaceuticals logo
Deciphera Pharmaceuticals

Associate Director, Marketing – Romvimza

Waltham, MA (On-site)

$174K/yr – $239K/yrSenior Level10+ years expFull time

Posted 3 weeks ago

  • Job
  • Company
  • Salaries
  • People
  • Funding
  • Audience
  • News
  • Links

Job Summary

Own the end-to-end marketing plan and digital strategy for the brand, driving cross-functional execution with a patient-centered voice and a strong focus on HCP engagement and measurement.

  • Lead integrated plan development, materials creation, and field programs
  • Own measurement, analytics, and optimization with cross-functional partners

Job Description

Responsibilities

  • Support the development of an integrated marketing plan and drive execution (40%)
  • Create and deliver core disease state and branded materials, ensuring alignment with brand strategy
  • Develop field sales materials and programs with consistent pull-through of messaging
  • Serve as a brand champion by helping train, motivate, and inspire the commercial team to bring the brand strategy to life while keeping the voice of the patient central to execution
  • Build and execute comprehensive digital marketing and non-personal promotion strategies (40%)
  • Align with brand objectives, focusing on HCP engagement, awareness and activation across various media channels including programmatic, custom units, social media, paid search, CRM, etc.
  • Support the brand planning, tactical planning, and budget management process to ensure initiatives are delivered on time and on budget
  • Collaborate efficiently and effectively with agencies and cross-functional partners including sales, training, medical affairs, analytics, legal, and regulatory
  • Support development and implementation of measurement plan for marketing initiatives (20%)
  • Utilize advanced analytics, qualitative insights, competitive intelligence, and field feedback to assess the effectiveness of initiatives and refine strategies as needed based upon evolving business needs

Requirements

  • Bachelor’s degree in a relevant business-related and/or life sciences field required with 10 years of experience in pharma/biotech marketing
  • Experience in HCP and digital marketing
  • Oncology and/or rare disease experience
  • Strategic thinking, including being creative in addressing key challenges, applying innovative ideas, and taking measured risks
  • Effective project management skills to enable pull-through of marketing initiatives
  • Strong organizational skills with excellent attention to detail
  • Ability to thrive independently and in ambiguity, with an entrepreneurial mind-set and with a track record of exploring new ways of working, driving new opportunities and catalyzing others to build creative solutions
  • Operational knowledge of medical, regulatory, legal review process
  • Eager to work in a fast-paced environment, striving for excellence in everything we do, alongside a team driven by improving the lives of patients
  • Ability to travel (10-25%)

Preferred

  • An MBA or advanced degree preferred

Benefits

  • Benefits: - Competitive salary and annual bonus. - Comprehensive benefits package including medical, dental, vision insurance, 401(k) retirement plan with company match, and more. - Generous parental leave and family planning benefits. - Outstanding culture and opportunities for personal and professional growth.
Deciphera Pharmaceuticals logo

Deciphera Pharmaceuticals

4.3 Glassdoor

As a member of ONO Group, Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. For more information, visit www.deciphera.com.

Founded in 2003
Waltham, Massachusetts, USA
511 employees (17 in marketing)
www.deciphera.com
92% recommend to a friend
97% CEO approval

Salaries

Posted range

$174K/yr – $239K/yr

Taken straight from the job posting.

See all Deciphera Pharmaceuticals salaries

Marketing Team

Marketing Team Size
17 (3% of company)
Median Career Experience
10 years
Median Tenure
2.5 years
Marketing Roles Posted (Last 30 Days)
3

People

Marketing Leadership

Craig Laferty
Craig Laferty
Sr. Director, Hematology Marketing
At the company for 3 months
Taylor Harris
Taylor Harris
Senior Manager, Brand Marketing
At the company for 1 year

Funding

Total Funding
$1B
Last Raise
$125M
Post IPO Equity, 3 years ago

Funding History

  • Jan 2023
    Post IPO Equity • $125M
  • Apr 2022
    Post IPO Equity • $172.5M
  • Aug 2019
    Post IPO Equity • $400M

Traffic Signals

Monthly Visitors
9.9K
Traffic Source Mix
Search
47.4%
Direct
40.3%
Referral
5.4%
Social
5.4%
Paid
1.3%

Headcount Trend

Current headcount: ~511

Recent News

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting
Dec 6, 2025 • Business Wire
Deciphera Announces the Opening of a New Office in Zug, Switzerland
Nov 17, 2025 • Business Wire
Deciphera Announces Multiple Data Presentations at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2025
Nov 12, 2025 • Business Wire
Deciphera’s Oncology Portfolio Fuels Parent Company’s Record Performance
Oct 31, 2025 • AD HOC NEWS
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025
Oct 18, 2025 • Business Wire
European Commission approves ROMVIMZA for TGCT treatment
Sep 18, 2025 • PharmaTimes
Deciphera gets European Commission approval of Romvimza
Sep 18, 2025 • Pharma Letter
Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
Sep 18, 2025 • BioSpace
Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
Sep 17, 2025 • Business Wire
Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
Sep 17, 2025 • Yahoo Finance
Deciphera Receives European Commission Approval of ROMVIM...
Sep 17, 2025 • PharmiWeb
Deciphera Pharmaceuticals patents new ULK1 and ULK2 inhibitors
Aug 29, 2025 • BioWorld MedTech
ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer
Aug 18, 2025 • ORIC Pharmaceuticals
Oncology Companion Diagnostics Market Driven by Targeted Therapies & Biomarker Advances | DataM Intelligence
Jul 31, 2025 • EIN Presswire
Deciphera Announces Positive CHMP Opinion for ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
Jul 29, 2025 • BioSpace
EMA Recommends Romvimza for Tenosynovial Giant Cell Tumor
Jul 28, 2025 • Medscape
Deciphera Announces Positive CHMP Opinion for ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
Jul 28, 2025 • Business Wire
Lilly's appeal unlocks EU approval of Alzheimer's drug
Jul 28, 2025 • pharmaphorum
Europe's CHMP gives thumbs-up to Lilly's Kisunla and Gilead's long-acting PrEP drug Yeytuo
Jul 25, 2025 • FiercePharma
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for ROMVIMZA™ (vimseltinib)
Jun 23, 2025 • Onco360 Oncology Pharmacy
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for QINLOCK® (ripretinib)
Jun 20, 2025 • Onco360 Oncology Pharmacy
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for QINLOCK® (ripretinib)
Jun 20, 2025 • BioSpace
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for QINLOCK® (ripretinib)
Jun 20, 2025 • Morningstar.com
Biotech Powerhouse Behind $2.4B Deciphera Sale Joins JP Morgan Life Sciences VC
May 19, 2025 • Stock Titan
Fierce Pharma Asia—Akeso bispecific's first survival readout; AstraZeneca's China probes; Ono's layoffs
May 2, 2025 • FiercePharma
Tendinopathy Pipeline Insight 2025 | Breakthrough in Tendon Pain: Over 5 Pipeline Drugs in Development Unveiled
Apr 30, 2025 • Research and Markets
Gastrointestinal Stromal Tumor Market to Grow Rapidly During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight
Apr 15, 2025 • DelveInsight Business Research LLP
Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade
Mar 12, 2025 • Benzinga
Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight
Mar 4, 2025 • PR Newswire
FDA Approves Romvimza for Symptomatic Tenosynovial Giant Cell Tumor
Feb 20, 2025 • Specialty Pharmacy Continuum
Vimseltinib gains FDA approval for treating tenosynovial giant cell tumor
Feb 20, 2025 • News-Medical.Net
FDA approves Deciphera’s Romvimza for rare tumour type
Feb 20, 2025 • PharmaTimes
Deciphera’s Romvimza wins FDA nod for tenosynovial giant cell tumors
Feb 18, 2025 • BioWorld MedTech
Ono Pharma Drug Acquired in $2.4B Deal Wins FDA Approval for Treating Rare Type of Tumor
Feb 18, 2025 • MedCity News
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
Feb 17, 2025 • BioSpace
Ono’s FDA Rare Cancer Approval Sets Up Face Off With Daiichi Sankyo
Feb 17, 2025 • BioSpace
FDA approves rare tumor drug Romvimza
Feb 17, 2025 • Pharma Letter
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
Feb 14, 2025 • Business Wire
Ono wins FDA approval for TGCT treatment gained via Deciphera takeout
Feb 14, 2025 • FirstWord Pharma
FDA approves Ono's rare tumor drug from $2.4B Deciphera buyout
Feb 14, 2025 • Fierce Pharma
Inhibitors of PERK and GCN2 disclosed in Deciphera patent
Dec 23, 2024 • BioWorld Financial Watch
Deciphera’s GCN2 activator shows activity in solid tumors
Oct 30, 2024 • BioWorld MedTech
Ono Pharmaceutical wraps up $2.4 billion Deciphera buyout
Jun 30, 2024 • Investing.com
Ono Pharmaceutical Closes Deciphera Deal for About $2.4 Billion
Jun 30, 2024 • Morningstar
Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)
Jun 30, 2024 • PR Newswire
Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from S&P Global BMI Index
Jun 10, 2024 • MarketScreener
ONO Pharmaceutical’s $2.4 Billion Acquisition of Deciphera Pharmaceuticals
May 9, 2024 • Global Legal Chronicle
Fierce Pharma Asia—Ono buys Deciphera for $2.4B; Novartis expands PeptiDream collab; WuXi Bio exits BIO 2024
May 3, 2024 • FiercePharma
Japan's Ono Pharma to buy U.S. drugmaker Deciphera for $2.4bn
May 1, 2024 • Nikkei Asia
Greenberg Traurig Represents ONO Pharmaceutical Co. in $2.4B Acquisition of Deciphera Pharmaceuticals
Apr 30, 2024 • PRWeb
Deciphera Pharmaceuticals divulges new PERK and GCN2 inhibitors
Jan 1, 1970 • http://www.zdnet.com/
The Latest Analyst Ratings for Deciphera Pharmaceuticals
Jan 1, 1970 • Benzinga
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 1, 1970 • Business Wire
Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results
Jan 1, 1970 • Business Wire
Deciphera Pharmaceuticals GAAP EPS of -$0.58 beats by $0.03, revenue of $43.31M beats by $4.08M
Jan 1, 1970 • SeekingAlpha
Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
Jan 1, 1970 • Morningstar
Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results
Jan 1, 1970 • BioSpace
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 1, 1970 • Business Wire
Deciphera Pharmaceuticals Sees Renewed Competitive Edge After Theseus Pan-KIT Discontinuation: Analyst
Jan 1, 1970 • TradingView
Deciphera Pharmaceuticals Announces First Quarter 2023 Financial Results
Jan 1, 1970 • BioSpace
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
Jan 1, 1970 • Business Wire

Links

www.deciphera.comLinkedInX (Twitter)Crunchbase